Skip to Content

Inogen appoints Glezer chief technology officer

Inogen appoints Glezer chief technology officer

GOLETA, Calif. – Inogen has named Stanislav Glezer, M.D., to the role of chief technology officer responsible for R&D and engineering, medical affairs and regulatory affairs. Glezer, who joined Inogen in June. will remain an executive vice president of the company. He has more than 27 years of experience, including expertise in the development and commercialization of combination drug device innovations, clinical development, medical and regulatory affairs as well as market access and has held leadership roles at a variety of medical technology and biotechnology firms, including Becton, Dickinson and Company, Adocia S.A., Novo Nordisk, Inc., and Sanofi S.A. “Since joining Inogen as chief medical officer earlier this year, Stan has made a significant impact in helping us instill clinically-informed discipline in innovation, product development practices and go-to-market strategy,” said Nabil Shabshab, president and CEO. “In this new role, Stan’s deep background in clinical research, success in developing, commercializing, and securing access for new innovations will be vital as we drive the next phase of growth and shareholder value creation.” Inogen also announced that Brenton Taylor, Executive Vice President, Engineering, will be leaving the Company after a transition period ending April 1, 2022.

Comments

To comment on this post, please log in to your account or set up an account now.